BeiGene

BeiGene to use Medidata’s patient cloud ePRO solution

Tuesday, July 25, 2017

Medidata, a global provider of cloud-based technology and data analytics for clinical research, announced that BeiGene, a clinical-stage biopharmaceutical company developing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, will expand its use of the Medidata Clinical Cloud to further digitize patient reporting for its oncology research studies.

[Read More]

Report: Slowest quarter for venture-backed IPOs since 2011

Tuesday, April 5, 2016

Six venture-backed initial public offerings (IPOs) raised $574.5 million in the first quarter of 2016, according to the Exit Poll Report by Thomson Reuters and the National Venture Capital Association (NVCA). This marks the slowest quarter for venture-backed IPOs since the third quarter of 2011. By merger and acquisition (M&A), 79 venture-backed M&A deals were reported in the first quarter, 20 of which reported an aggregate deal value of $4.8 billion.   

[Read More]

Merck, BeiGene ink global agreement

Monday, November 18, 2013

Merck Serono has signed a global licensing, co-development and commercialization agreement with BeiGene, an R&D  biotech  in Beijing, for the compound BeiGene-290. The compound, a potent poly (ADP-ribose) polymerase (PARP) inhibitor for the treatment of cancer, currently is in preclinical development and is expected to enter clinical development next year. This is the second collaboration agreement between the two companies this year.

[Read More]